Fondaparinux: Pharmacology and clinical experience in cardiovascular medicine

Vincenzo Toschi, M. Lettino

Research output: Contribution to journalArticle

Abstract

Fondaparinux is a synthetic, five-saccharide chain, AT-dependent, anti-FXa agent. Studies showed that fondaparinux acts in prevention and treatment of venous thromboembolism and in ischemic heart disease, without significant bleeding risk. The drug inhibits thrombin generation, has long half-life and can be administered once-daily without laboratory monitoring. It may be used in HIT treatment.

Original languageEnglish
Pages (from-to)383-387
Number of pages5
JournalMini-Reviews in Medicinal Chemistry
Volume7
Issue number4
DOIs
Publication statusPublished - Apr 2007

Fingerprint

Clinical Pharmacology
Medicine
Venous Thromboembolism
Thrombin
Myocardial Ischemia
Half-Life
Hemorrhage
Monitoring
Pharmaceutical Preparations
fondaparinux

Keywords

  • Antithrombotic
  • Factor Xa inhibitor
  • Fondaparinux
  • Heparin
  • Low molecular weight heparin

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Chemistry(all)
  • Pharmacology

Cite this

Fondaparinux : Pharmacology and clinical experience in cardiovascular medicine. / Toschi, Vincenzo; Lettino, M.

In: Mini-Reviews in Medicinal Chemistry, Vol. 7, No. 4, 04.2007, p. 383-387.

Research output: Contribution to journalArticle

@article{2fcd92e4510940a5bbf55cf5650a0205,
title = "Fondaparinux: Pharmacology and clinical experience in cardiovascular medicine",
abstract = "Fondaparinux is a synthetic, five-saccharide chain, AT-dependent, anti-FXa agent. Studies showed that fondaparinux acts in prevention and treatment of venous thromboembolism and in ischemic heart disease, without significant bleeding risk. The drug inhibits thrombin generation, has long half-life and can be administered once-daily without laboratory monitoring. It may be used in HIT treatment.",
keywords = "Antithrombotic, Factor Xa inhibitor, Fondaparinux, Heparin, Low molecular weight heparin",
author = "Vincenzo Toschi and M. Lettino",
year = "2007",
month = "4",
doi = "10.2174/138955707780363819",
language = "English",
volume = "7",
pages = "383--387",
journal = "Mini-Reviews in Medicinal Chemistry",
issn = "1389-5575",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Fondaparinux

T2 - Pharmacology and clinical experience in cardiovascular medicine

AU - Toschi, Vincenzo

AU - Lettino, M.

PY - 2007/4

Y1 - 2007/4

N2 - Fondaparinux is a synthetic, five-saccharide chain, AT-dependent, anti-FXa agent. Studies showed that fondaparinux acts in prevention and treatment of venous thromboembolism and in ischemic heart disease, without significant bleeding risk. The drug inhibits thrombin generation, has long half-life and can be administered once-daily without laboratory monitoring. It may be used in HIT treatment.

AB - Fondaparinux is a synthetic, five-saccharide chain, AT-dependent, anti-FXa agent. Studies showed that fondaparinux acts in prevention and treatment of venous thromboembolism and in ischemic heart disease, without significant bleeding risk. The drug inhibits thrombin generation, has long half-life and can be administered once-daily without laboratory monitoring. It may be used in HIT treatment.

KW - Antithrombotic

KW - Factor Xa inhibitor

KW - Fondaparinux

KW - Heparin

KW - Low molecular weight heparin

UR - http://www.scopus.com/inward/record.url?scp=34247634186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247634186&partnerID=8YFLogxK

U2 - 10.2174/138955707780363819

DO - 10.2174/138955707780363819

M3 - Article

C2 - 17430224

AN - SCOPUS:34247634186

VL - 7

SP - 383

EP - 387

JO - Mini-Reviews in Medicinal Chemistry

JF - Mini-Reviews in Medicinal Chemistry

SN - 1389-5575

IS - 4

ER -